Effect between Clomiphene Citrate plus Metformin and Clomiphene Citrate Alone on Induction of Ovulation in Women with Polycystic Ovarian Syndrome

Background: PCOS is a common metabolic and reproductive disorder that affects women and causes its symptoms and signs. It is estimated that 4% of women of reproductive age worldwide are affected; however, in populations with a higher risk, some estimates place the percentage closer to 10%. Aim of this study is to determine and compare the rates of ovulation, menstrual cycle regularization, and pregnancy in PCOS patients taking both clomiphene citrate and metformin in combination and clomiphene citrate alone. Methods: Between March 2023 and February 2024, 220 patients, 110 in each group, with primary subfertility and PCOS diagnoses who were between the ages of 18 and 40 were selected. The primary outcome, or the incidence of ovulation, was determined by folliculometry. Secondary outcomes that were compared between the two groups were the regularization of the menstrual cycle and the frequencies of pregnancy. Results: Overall ovulation was shown to be at its maximum during the third cycle of ovulation induction, occurring in each group at 48.8% and 41%, respectively. The primary outcome for group A was significantly higher (83.3%) when clomiphene citrate and metformin were administered jointly than when clomiphene citrate was administered alone (65.9%). The secondary results were significantly greater (89.6%) in the group that received metformin with CC. Pregnancy rates were higher in the first group (33.3%) than in the second (20.5%). Conclusion: Two groups were given varying quantities of clomiphene citrate in this study: one group had it in addition to metformin, while the other group received it just to induce ovulation. It was found that clomiphene citrate plus metformin was a better way to induce ovulation in women with PCOS than clomiphene citrate alone.